Samples: from the Patient to the Laboratory
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Meriam Abbas
Meriam Abbas 1970, 153 cm colour of hair: dark brown colour of eyes: dark brown languages: German, Arabic (2nd mother tongue), English accent: berlinerisch, wienerisch vocal range: soprano singing: stage singing instruments: flute sports: horse riding, ski dance: standard driver’s licence: car (B) residence: Berlin accomodation possible in: Hamburg, Cologne, Hannover, Frankfurt a.M., Leipzig, Munich, Stuttgart, Vienna film selection: director: 2020 BILDERKRIEGERIN (AT) Roman Kuhn 2019 DIE PFEFFERKÖRNER UND DER SCHATZ DER TIEFSEE Christian Theede 2019 CONTRA Sönke Wortmann 2019 OUR RIVER… OUR SKY Maysoon Pachachi 2017 BAGHDAD IN MY SHADOW Samir world premiere at Locarno Film Festival 2019 2016 FREMDE TOCHTER Stephan Lacant world premiere at Filmfest Munich 2017 2012 BERLIN -7° (AT) Ramtin Lavafipour 2011 SHAITAN, HFF graduation film Ersin Cilesiz 2009 ROT GOLD SCHWARZ, shortfilm Filmakademie Baden-Württemberg Verena Jahnke world premiere at Filmfestival Max Ophüls Preis in January 2010 … / 2 Oesterleystraße 3, 22587 Hamburg tel. 040 .589 689 64, mobil 0173 – 244 48 88 [email protected] , www.sandrarudorff.de sandra rudorff künstleragentur – Meriam Abbas cv – page 2 2009 WASSERHÄRTENGRADE, short film HFBK Hamburg Sonja Dürscheid 2008 AB JETZT SIND WIR ANDERS Sobo Swobodnik world premiere at Filmfestival Max Ophüls Preis in January 2009 2004 UNDEREXPOSURE, iraqi Oday Rasheed 2000 DREI STERN ROT Olaf Kaiser 1999 NACHTGESTALTEN (lead) Andreas Dresen tv selection: director: channel: 2020 GROSSSTADTREVIER: Stumme Signale (AT)Torsten Wacker -
Coagulation Testing: High Hematocrit-Anticoagulant Adjustment
PREANALYTIC PULSE Coagulation Testing: High Hematocrit-Anticoagulant Adjustment In 1980, CLSI released H21-A4 guidelines for coagulation testing, which included the recommendation to adjust/correct the amount of citrate in blue-top evacuated blood collection tubes for patients presenting hematocrits greater than 55%. In addition to the CLSI guidelines, the CAP hematology checklist HEM.22830 includes the question, “Are there documented guidelines for the detection and special handling of specimens with elevated hematocrits?” Principle The adjustment is to assure the plasma:anticoagulant ratio (not the blood:anticoagulant ratio) stays consistent. A patient with high hematocrit, greater than 55%, will result in less plasma after centrifugation. The plasma fraction will contain an increased concentration of sodium citrate anticoagulant. The increased concentration may result in falsely prolonged test results for Prothrombin Time (PT) and Activated Partial Thromboplastin Time (aPTT). Formula 1. To calculate the corrected 3.2% sodium citrated whole blood for hematocrit > 55%, adjust the citrate to the proper volume with the following formula: -3 C = (1.85 x 10 )(100-HCT)(Vblood) Where: C = volume of sodium citrate required for that volume of blood HCT = patient’s hematocrit V = volume of blood required in the blood collection tube (example if a 3mL tube is used the blood draw volume is 2.7mL) 1.85 x 10-3 is a constant (considering the citrate volume, blood volume, and citrate concentration). 2. Example: Patient has a Hct of 60% and the patient’s blood will be drawn into a 3mL VACUETTE® sodium citrate (blue-top) blood collection tube. Adjustment of the sodium citrate volume is calculated as: C = (1.85 x 10-3)(100-60)(2.7mL) C = 0.20mL (rounded up from 01.998mL) Remove: 0.30 - 0.20 = 0.10mL of sodium citrate to be removed (0.30 is the difference between the total tube volume of 3.0mL and the blood drawn into the tube of 2.7mL) Method The instructions to prepare an adjusted sodium citrate tube are to be documented in the Laboratory Standard Operating Procedures. -
Role of Real-Time / Accurate Diagnostic Testing in Patient Blood Management Programs
ROLE OF REAL-TIME / ACCURATE DIAGNOSTIC TESTING IN PATIENT BLOOD MANAGEMENT PROGRAMS POINT-OF-CARE TESTING “Diagnostic testing is an essential component of Patient Blood Management. The accurate assessment of the true causes of bleeding dysfunction facilitates the employment of evidence based, goal directed therapy to rapidly prevent and treat excess blood loss. “ Sherri Ozawa RN, Clinical Director, Institute of Patient Blood Management, Englewood Hospital Medical Center, Englewood, New Jersey. PATIENT BLOOD MANAGEMENT Interdisciplinary Managing Blood Conservation Anemia Modalities “The timely application of evidence based medical and surgical concepts designed to manage IMPROVED anemia, optimize hemostasis, and PATIENT minimize blood loss in order to OUTCOMES improve patient outcomes.” SABM© 2018 - Society for the Advancement of Blood Management (SABM.org) Optimizing Patient-Centered Coagulation Decision Making Point-of-care testing forms an integral part of PBM, enabling accurate and real-time diagnosis of anemia and bleeding and facilitating precise and targeted hemostatic intervention. 1 Conventional coagulation tests are unable to provide needed information on actual bleeding risk/defects 1, thus delaying appropriate and targeted treatment. Slow turnaround times for laboratory-based conventional coagulation tests are one of the major drivers of empirical treatment regimens, which inevitably result in some patients receiving unnecessary, inappropriate and avoidable transfusions, with associated increased morbidity and mortality, and -
Global Assays of Hemostasis in the Diagnostics of Hypercoagulation and Evaluation of Thrombosis Risk Elena N Lipets1 and Fazoil I Ataullakhanov1,2,3,4,5,6*
Lipets and Ataullakhanov Thrombosis Journal (2015) 13:4 DOI 10.1186/s12959-015-0038-0 REVIEW Open Access Global assays of hemostasis in the diagnostics of hypercoagulation and evaluation of thrombosis risk Elena N Lipets1 and Fazoil I Ataullakhanov1,2,3,4,5,6* Abstract Thrombosis is a deadly malfunctioning of the hemostatic system occurring in numerous conditions and states, from surgery and pregnancy to cancer, sepsis and infarction. Despite availability of antithrombotic agents and vast clinical experience justifying their use, thrombosis is still responsible for a lion’s share of mortality and morbidity in the modern world. One of the key reasons behind this is notorious insensitivity of traditional coagulation assays to hypercoagulation and their inability to evaluate thrombotic risks; specific molecular markers are more successful but suffer from numerous disadvantages. A possible solution is proposed by use of global, or integral, assays that aim to mimic and reflect the major physiological aspects of hemostasis process in vitro. Here we review the existing evidence regarding the ability of both established and novel global assays (thrombin generation, thrombelastography, thrombodynamics, flow perfusion chambers) to evaluate thrombotic risk in specific disorders. The biochemical nature of this risk and its detectability by analysis of blood state in principle are also discussed. We conclude that existing global assays have a potential to be an important tool of hypercoagulation diagnostics. However, their lack of standardization currently impedes their application: different assays and different modifications of each assay vary in their sensitivity and specificity for each specific pathology. In addition, it remains to be seen how their sensitivity to hypercoagulation (even when they can reliably detect groups with different risk of thrombosis) can be used for clinical decisions: the risk difference between such groups is statistically significant, but not large. -
64Th Annual SSC Meeting, in Conjunction with the 2018 ISTH Congress in Dublin, Ireland Meeting Minutes Standing Committees Coagulation Standards Committee
64th Annual SSC meeting, in conjunction with the 2018 ISTH Congress in Dublin, Ireland Meeting Minutes Standing Committees Coagulation Standards Committee............................................................... 3 Subcommittees Animal, Cellular and Molecular Models ........................................................ 6 Biorheology .................................................................................................. 9 Control of Anticoagulation ............................................................................ 15 Disseminated Intravascular Coagulation ...................................................... 20 Factor VIII, Factor IX and Rare Coagulation Disorders ................................ 23 Factor XI and the Contact System ............................................................... 27 Factor XIII and Fibrinogen ............................................................................ 30 Fibrinolysis ................................................................................................... 34 Genomics in Thrombosis and Hemostasis ................................................... 38 Hemostasis and Malignancy ........................................................................ 47 Lupus Anticoagulant/Phospholipid Dependent Antibodies ........................... 51 Pediatric and Neonatal Hemostasis and Thrombosis ................................... 57 Perioperative and Critical Care Thrombosis and Hemostasis ...................... 66 Plasma Coagulation Inhibitors ..................................................................... -
Regionale Kulturförderung Des Landschaftsverbandes Rheinland 2019
Die Direktorin des Landschaftsverbandes Rheinland Vorlage-Nr. 14/3070 öffentlich Datum: 15.11.2018 Dienststelle: Fachbereich 91 Bearbeitung: Frau Loke / Frau Wollgarten Kulturausschuss 28.11.2018 empfehlender Beschluss Finanz- und 12.12.2018 empfehlender Beschluss Wirtschaftsausschuss Landschaftsausschuss 14.12.2018 Beschluss Tagesordnungspunkt: Regionale Kulturförderung des Landschaftsverbandes Rheinland 2019 Beschlussvorschlag: 1. Den in den Anlagen 1 und 2 zur Vorlage 14/3070 aufgeführten Projekten mit einem Fördervolumen in Höhe von 5.537.367,00 EUR im Rahmen der Regionalen Kulturförderung wird entsprechend der Empfehlung der Kommission Rheinlandtaler und Regionale Kulturförderung zugestimmt. 2. Die nicht projektgebundenen und somit verbleibenden GFG-Mittel in Höhe von 3.752,95 EUR werden im Rahmen der Regionalen Kulturförderung 2020 für Fortsetzungsprojekte verwendet. 3. Dem künftigen Umgang mit sog. Fortsetzungsprojekten wird wie in der Vorlage dargestellt zugestimmt. 4. Für Fortsetzungsprojekte sind für das Jahr 2020 aktuell 1.695.300,00 EUR und für das Jahr 2021 aktuell 30.000,00 EUR vorgemerkt. 5. Den für die Ziffern 1 und 2 des Beschlussvorschlages erforderlichen außer- und überplanmäßigen Erträgen und Aufwendungen sowie die Einzahlungen und Auszahlungen bei Investitionstätigkeiten wird zugestimmt. 6. Die Deckung der Aufwendungen bzw. Auszahlungen zu den Ziffern 1 und 2 des Beschlussvorschlages erfolgt durch umlageneutrale, pauschale allgemeine Landeszuweisungen nach dem Gemeindefinanzierungsgesetz (GFG). 7. Die als Anlage 3 -
Pre-Analytical Variables in the Coagulation Lab: Why Does It Matter?
Generate Knowledge Pre-Analytical Variables in the Coagulation Lab: Why Does It Matter? Paul Riley, PhD, MBA Pre-Analytical Variables: Objectives 1. Define Pre-Analytical variables 2. Explain how blood collection may impact test results 3. Describe best practices for sample transport and storage 4. Review sample processing procedures 5. Identify patient variables that may affect coagulation testing What are Pre-Analytical Variables? Includes everything that may affect a patient specimen from the clinician ordering the test to the point of analysis Some patient variables are out of the lab’s control (medications, lipemia, icterus, etc.) The biggest source of laboratory error - far exceeds analytical error Scope? Up to 70% of testing errors occur in the pre-analytical phase1 It is not always clear when a sample is received in the lab that it may be unsuitable or compromised Lab results lead to clinical action 70-80% of all clinical decisions regarding patient care are based on lab results Coag samples are especially susceptible Sample collection initiates clotting PT and PTT are complex enzymatic reactions 1. Plebani M: Quality indicators to detect pre-analytical errors in Laboratory testing. Clin Biochem Rev 2012; 33:85-88 Scope? What are the ramifications of pre-analytical errors for the patient? Misdiagnosis Inappropriate treatment Diligence is required on the part of the laboratory to prevent incorrect results Must have quality indicators in place to monitor the steps of the pre- analytical phase Event management where errors are investigated and corrected so that repeat events are prevented Scope? When a sample is compromised: • the test result may reflect the status of the sample • but not reflect the clinical status of the patient Guidelines In order to improve the quality of patients results, sample collection and handling should follow the CLSI guideline H21-A5; 2008 Test Ordering Is the right test ordered on the right patient? Coag is confusing - Names sound alike! Factor X vs. -
Mennonitische Geschichtsblätter
Mennonitische Geschichtsblätter 1. bis 73. Jahrgang (1936 – 1940 und 1949 – 2016) Gesamtregister 2., aktualisierte und überarbeitete Auflage erarbeitet von Helmut Foth Mennonitische Geschichtsblätter herausgegeben vom Mennonitischen Geschichtsverein e.V. Bolanden – Weierhof ISSN 0342-1171 Schriftleitung: Prof. Dr. Hans-Jürgen Goertz, Hamburg Priv.– Doz. Dr. Marion Kobelt – Groch, Timmendorfer Strand Ulrike Arnold, Eschwege Mennonitische Geschichtsblätter 1936 – 2016 Gesamtregister Gesamtregister Mennonitische Geschichtsblätter 1. – 73. Jahrgang (1936 – 1940 und 1949 – 2016) Inhalt: Vorwort zur zweiten Auflage ......................................................... 3 Vorwort ............................................................................................. 3 Praktische Hinweise ......................................................................... 5 Stichwortverzeichnis ....................................................................... 7 Titelseite von Jahrgang 1936 .......................................................... 10 Titelseite von Jahrgang 2016 .......................................................... 11 I. Autorinnen und Autoren .............................................................. 12 II. Sachregister ................................................................................. 47 III. Rezensionen ............................................................................... 195 IV. Festschriften ............................................................................... 225 V. Laudationes -
Laboratory-General Specimen Collection and Handling Guidelines
Laboratory-General Specimen Collection and Handling Guidelines Contents: Microbiology continued. Orders/Requests Stool Patient Preparation Throat or Pharynx Specimen Containers Tuberculosis (TB) Specimen Quality Urine Order of Draw Viral Specimen Transport VRE Surveillance (Vancomycin- Resistant entercoccus) Specimen Rejection Wound General Lab Sample/Source: Whole Blood Cytology (Cytopathology) Plasma Aspiration, Fine Needle Serum Aspiration, Cyst Fluids Urine Submission of slide Fecal (Stool) Tips on making smears Body Fluid Body Cavity Fluids Cerebrospinal Spinal Fluid Breast Nipple Secretions Synovial Fluid Brushing Specimens Microbiology Cerebrospinal Fluid (CSF) Sample/Source: Ectocervix, Endocervical canal, Vaginal pool Abscess (Deep aspirate) Pap Smear, Conventional Abscess (superficial swab) Pap Smear, Liquid Base Acid Fast Bacillus (AFB) Sputum Specimens Anaerobic Surface Scrape Specimen (Tzanck Smear) Aspirate, drainage, cyst fluid, or pustule Vaginal Wall (Maturation Index) Biopsy, Bone, Tissue Washing Specimens Blood (Adult) Histology (Anatomic Pathology) Blood )Pediatric Routine Submission Blood for Acid Fast Bacillus (AFB) Fresh Specimen Body Fluids Surgical Specimen and Microbiology test(s) Bronchial Washing Lavage Breast Tissue Catheter Tip Brushing Specimens C. difficile Toxin B Bronchial Washing and Brushings Chlamydia/Gonorrhea Amplified Detection Muscle Biopsy Crytococcal Antigen Renal Biopsy (Kidney) Cerebral Spinal Fluid (CSF) Renal calculi (Kidney/Bladder Stones) Ear (outer) Bone Marrow Ear (inner) Cytogenics Eye -
Point of Care Coagulation Testing
POINT OF CARE COAGULATION TESTING Dr Danny Morland Royal Victoria Infirmary Newcastle upon Tyne 11 th October 2016 Introduction Declarations of Interest: None CONTENT Introduction to POCT Principles Interpretation Treatment Literature NUTH Experience Point Of Care Testing (POCT) Medical diagnostic testing at (or near) the point of care. POCT PROS CONS • Quick • Cost (potentially) • Convenient • Quality • Reliable • Training • Efficient • Workload • Recording • Risk of inappropriate decision-making Point of Care Coagulation Testing (POCCT) Viscoelastic properties of whole blood clot Thromboelastography = Thromboelastometry (TEG) (ROTEM) Purported Benefits over Standard Tests • Measures whole blood, not just plasma • Looks at clot generation and propagation beyond the point of clot appearance • Allows comment on clot ‘quality’ • Can identify fibrinolysis FAST –potential information on clotting status within 5mins of test starting POCCT vs Standard Lab Tests POCCT LAB • Whole blood • Highly standardised • Clot beyond first • Trained, professional staff appearance • Quality control • Clot quality • Well established • Identify fibrinolysis • Complete picture • FAST • Cost PRINCIPLES Viscoelasticity Hardware OUTPUTS Panel Testing – Normal results INTERPRETATION Normal Low Platelets Normal Hypo-fibrinogenaemia Heparin Effect Normal TREATMENT LIMITATIONS AND WARNINGS • Treatment should be administered according to the clinical picture (e.g. volume & current rate of blood loss) • Viscoelastic devices are not uniformly sensitive to all disturbances -
The Summer Issue
GFQ3_18_Druckvorlage.qxp_Layout 1 25.07.18 14:47 Seite 1 GFQ GERMAN FILMS QUARTERLY THE SUMMER ISSUE IN LOCARNO Concorso internazionale GERMANY. A WINTER’S TALE by Jan Bonny Piazza Grande WHAT DOESN’T KILL US by Sandra Nettelbeck Concorso Cineasti del presente ALL GOOD by Eva Trobisch IN VENICE In Competition NEVER LOOK AWAY by Florian Henckel von Donnersmarck DIRECTORS Angela Schanelec & Robert Schwentke PRODUCERS Schiwago Film ACTOR Bjarne Mädel ISSUE 3-2018 GFQ3_18_Druckvorlage.qxp_Layout 1 25.07.18 14:47 Seite 2 CONTENTS GFQ 3-2018 18 20 23 24 26 28 29 30 32 35 36 36 2 GFQ3_18_Druckvorlage.qxp_Layout 1 25.07.18 14:47 Seite 3 GFQ 3-2018 CONTENTS IN THIS ISSUE PORTRAITS NEW DOCUMENTARIES LIFE IN THE TIME OF NO BELONGING DEFENDER OF THE FAITH A portrait of director Angela Schanelec .......................................... 4 Christoph Röhl ................................................................................. 34 AT HOME IN TWO WORLDS DIE GEHEIMNISSE DES SCHÖNEN LEO A portrait of director Robert Schwentke ......................................... 6 THE SECRETS OF HANDSOME LEO Benedikt Schwarzer .............. 34 HANDS ON PRODUCERS STILLER KAMERAD A portrait of Schiwago Film .............................................................. 8 SILENT COMRADE Leonhard Hollmann .......................................... 35 IN SEARCH OF NEW CHALLENGES SUNSET OVER MULHOLLAND DRIVE A portrait of actor Bjarne Mädel ....................................................... 10 Uli Gaulke ......................................................................................... -
PDF Download
364 Review Article Can We Measure the Individual Prothrombotic or Prohemorrhagic Tendency by Global Coagulation Tests? Ã Ã Sara Reda1, Laure Morimont2,3, Jonathan Douxfils2,3 Heiko Rühl1 1 Institute of Experimental Hematology and Transfusion Medicine, Address for correspondence Heiko Rühl, MD, Institute of University of Bonn, Bonn, Germany Experimental Hematology and Transfusion Medicine, University of 2 Department of Pharmacy, Namur Thrombosis and Hemostasis Bonn, Venusberg-Campus 1, 53127 Bonn, Germany Center,UniversityofNamur,Namur,Belgium (e-mail: [email protected]). 3 Qualiblood s.a., Namur, Belgium Hämostaseologie 2020;40:364–378. Abstract Hemostasis is a complex process in which abnormalities can cause shifts toward prothrombotic or prohemorrhagic states resulting in thrombosis or bleeding, respec- tively. Several coagulation tests may be required to characterize these defects but may yet not always reflect a patient’s true hemostatic capacity. Thus, global coagulation tests aiming to simulate the coagulation process in vitro instead of measuring single components thereof are certainly of interest to assess prothrombotic or prohemor- rhagic tendencies. This review describes the development and application of global Keywords coagulation tests, concentrating on the more widely used methods of viscoelastometry ► global coagulation and thrombin generation. A focus is placed on conditions characterized by simulta- tests neous changes of various components of hemostasis, such as anticoagulant therapy or ► hypercoagulability hormone-induced coagulopathy, in which global coagulation tests are especially ► bleeding promising. If the key challenges of standardization and automation of these tests ► anticoagulant drugs are solved, as is the case with automated thrombogram or clot waveform analysis, ► hormone-induced global coagulation assays will play an important role in the future of laboratory coagulopathy diagnostics of hemostasis and thrombosis.